var data={"title":"Clonidine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clonidine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5928?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clonidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clonidine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=clonidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clonidine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708678\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Epidural use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The 500 mcg/mL strength product should be diluted prior to use in an appropriate solution.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Note: Epidural clonidine is not recommended for obstetrical, postpartum, or perioperative pain management. The risk of hemodynamic instability, especially hypotension and bradycardia, from epidural clonidine may be unacceptable in these patients. However, in a rare obstetrical, postpartum or perioperative patient, potential benefits may outweigh the possible risks.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153485\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Catapres;</li>\n      <li>Catapres-TTS-1;</li>\n      <li>Catapres-TTS-2;</li>\n      <li>Catapres-TTS-3;</li>\n      <li>Duraclon;</li>\n      <li>Kapvay</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153486\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Catapres;</li>\n      <li>Dixarit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153534\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha<sub>2</sub>-Adrenergic Agonist;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153489\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles. Compounded oral suspensions may be available in multiple concentrations (up to 10-times more concentrated); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mcg or mg as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: Initial dose: 0.1 mg twice daily (maximum recommended dose: 2.4 mg/day); usual dose range (ASH/ISH [Weber 2014]): 0.1 to 0.2 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Initial: 0.1 mg/24 hour patch applied once every 7 days and increase by 0.1 mg at 1- to 2-week intervals (dosages &gt;0.6 mg/24 hours do not improve efficacy); usual dose range (ASH/ISH [Weber 2014]): 0.1 to 0.3 mg/24 hour patch applied once every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute hypertension (urgency) (off-label use):</b> Oral: Initial 0.1 to 0.2 mg; may be followed by additional doses of 0.1 mg every hour, if necessary, to a maximum total dose of 0.7 mg (Atkin 1992; Jaker 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Off-label route of administration: Sublingual: Initial: 0.1 to 0.2 mg; followed by 0.05 to 0.1 mg every hour until blood pressure controlled or a cumulative dose of 0.7 mg is reached (Cunningham 1994; Matuschka 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Clozapine-induced sialorrhea (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 0.05 mg at bedtime; if no improvement after 2 weeks, may increase to 0.1 mg at bedtime (Praharaj 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: 0.1 to 0.2 mg/24 hour patch applied once weekly (Grabowski 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Additional data may be necessary to further define the role of clonidine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nicotine withdrawal symptoms (off-label use) (Fiore 2008):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 0.1 mg twice daily; titrate by 0.1 mg/day every 7 days if needed; dosage range used in clinical trials: 0.15 to 0.75 mg/day; duration of therapy ranged from 3 to 10 weeks in clinical trials</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Initial: 0.1 mg/24 hour patch applied once every 7 days and increase by 0.1 mg at 1-week intervals if necessary; dosage range used in clinical trials: 0.1 to 0.2 mg/24 hour patch applied once every 7 days; duration of therapy ranged from 3 to 10 weeks in clinical trials</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid withdrawal (off-label use):</b> Oral: Immediate release: Initial: 0.1 mg to 0.2 mg every 6 to 8 hours; adjust dose based on the amount needed to control withdrawal symptoms (using the Clinical Opioid Withdrawal Scale [COWS]) and effect on blood pressure (APA [Kleber 2006]; Gowing 2016; Sevarino 2017). Inpatients may receive higher initial doses if blood pressure and sedation are closely monitored (APA [Kleber 2006]; Sevarino 2017). Dosage range: 0.1 to 0.3 mg every 6 to 8 hours (maximum: 1.2 mg/day) (APA [Kleber 2006]; ASAM [Kampman 2015]). <b>Note:</b> Clonidine may be combined with other non-narcotic medications (eg, benzodiazepines) (APA [Kleber 2006]; ASAM [Kampman 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tourette syndrome (off-label use):</b> Oral: Immediate release: Initial: 0.025 to 0.05 mg once daily; gradually increase dose based on response and tolerability up to a usual dosage of 0.1 to 0.6 mg/day in 3 to 4 divided doses (Murphy 2013; Pringsheim 2012; Roessner 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Epidural infusion: Reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics: Starting dose: 30 mcg/hour; titrate as required for relief of pain or presence of side effects; experience with doses &gt;40 mcg/hour is limited; should be considered an adjunct to opioid therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Conversion from oral to transdermal: </i> <b>Note:</b> If transitioning from oral to transdermal therapy, overlap oral regimen for 1 to 2 days; transdermal route takes 2 to 3 days to achieve therapeutic effects. An example transition is below:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 1: Place Catapres-TTS 1; administer 100% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 2: Administer 50% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 3: Administer 25% of oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Day 4: Patch remains, no further oral supplement necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conversion from transdermal to oral: </i>After transdermal patch removal, therapeutic clonidine levels persist for ~8 hours and then slowly decrease over several days. Consider starting oral clonidine no sooner than 8 hours after patch removal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153510\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=clonidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clonidine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles. Compounded oral suspensions may be available in multiple concentrations (up to 10-times more concentrated); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mcg or mg as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Hypertension (off-label use):</b> Oral: Children &ge;12 years: Immediate release: Initial: 0.2 mg/day in 2 divided doses; increase gradually, if needed, in 0.1 mg/day increments at weekly intervals; maximum: 2.4 mg/day (rarely required) (NHBPEP, Fourth Report)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Severe hypertension (off-label use):</b> Oral: Children: Immediate release: 0.05 to 0.1 mg/dose; may repeat up to a maximum total dose of 0.8 mg (NHBPEP, Fourth Report)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Clonidine tolerance test (test of growth hormone release from pituitary) (off-label use):</b> Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/m<sup>2</sup> as a single dose (Lanes 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/kg as a single dose; maximum dose: 250 mcg (Richmond 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>ADHD: </b> Oral: <b> Note:</b> May be used alone or as an adjunct to stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Immediate release</i> (off-label indication; Pliszka 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &le;45 kg: Initial: 0.05 mg at bedtime; sequentially increase every 3 to 7 days by 0.05 mg increments as twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.2 mg/day for patients weighing 27 to 40.5 kg; 0.3 mg/day for patients weighing 40.5 to 45 kg. When discontinuing therapy, taper gradually over 1 to 2 weeks. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt;45 kg: Initial: 0.1 mg at bedtime; sequentially increase every 3 to 7 days by 0.1 mg increments as twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.4 mg/day. When discontinuing therapy, taper gradually over 1 to 2 weeks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Extended release (Kapvay):</i> Children &ge;6 years: Initial: 0.1 mg at bedtime; increase in 0.1 mg/day increments every 7 days until desired response, doses should be administered twice daily in the morning and at bedtime (either split equally or with the higher split dosage given at bedtime); maximum daily dose: 0.4 mg/day. Note: When discontinuing therapy, taper daily dose by &le;0.1 mg every 3 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Conduct/oppositional-defiant disorder with or without ADHD (off-label use): </b> Children &ge; 5 years and Adolescents: Oral: Immediate release: Initial: 0.05 mg/day; gradual titration every 3 to 7 days in 0.05 mg increments to 2 to 3 times daily schedule has been used most frequently, some patients may require 4 daily doses; usual final dose range: 0.2 to 0.3 mg/day in 2-3 divided doses, reported overall range: 0.15 to 0.4 mg/day in divided doses; most reported experience in patients with ADHD comorbidity (Connor 2000; Kemph 1993; Palumbo 2008). Additional data may be necessary to further define the role of clonidine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tourette syndrome (off-label use):</b> Children &ge;7 years and Adolescents: Oral: Immediate release: Initial: 0.025 to 0.05 mg once daily; gradually increase dose based on response and tolerability using small increments (0.025 mg) up to a usual dosage of 0.1 to 0.4 mg/day in 3 to 4 divided doses (Murphy 2013; Pringsheim 2012; Roessner 2011; The Tourette's Syndrome Study Group 2002). <b>Note:</b> Greater efficacy shown in patients with ADHD comorbidity (Weisman 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pain management:</b> Epidural infusion: Reserved for cancer patients with severe intractable pain, unresponsive to other opioid analgesics: Initial: 0.5 mcg/kg/<b>hour</b>; adjust with caution, based on clinical effect </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153490\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b> Oral: Immediate release: Initial: 0.1 mg once daily at bedtime, increase gradually as needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153491\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Adults: Oral (immediate release), transdermal, epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, no specific dosage adjustment provided in manufacturer&rsquo;s labeling. Bradycardia, sedation, and hypotension may be more likely to occur in patients with renal failure; half-life significantly prolonged in patients with severe renal failure; consider use of lower initial doses and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Children: Oral (extended release), epidural: The manufacturer recommends dosage adjustment according to degree of renal impairment; however, no specific dosage adjustment provided (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary. Oral antihypertensive drugs given preferentially at night may reduce the nocturnal surge of blood pressure and minimize the intradialytic hypotension that may occur when taken the morning before a dialysis session (K/DOQI 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795877\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153455\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch Weekly, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-1: 0.1 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-2: 0.2 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres-TTS-3: 0.3 mg/24 hr (4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg/24 hr (1 ea, 4 ea); 0.2 mg/24 hr (1 ea, 4 ea); 0.3 mg/24 hr (1 ea, 4 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 100 mcg/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 100 mcg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duraclon: 500 mcg/mL (10 mL) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/mL (10 mL); 500 mcg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres: 0.1 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Catapres: 0.2 mg, 0.3 mg [scored; contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg, 0.2 mg, 0.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kapvay: 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153441\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23610340\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as hydrochloride: 0.025 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153460\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Epidural: Specialized techniques are required for continuous epidural administration; administration via this route should only be performed by qualified individuals familiar with the techniques of epidural administration and patient management problems associated with this route. Familiarization of the epidural infusion device is essential. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2 to 4 days to avoid withdrawal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be taken with or without food. Do not discontinue clonidine abruptly. If needed, gradually reduce dose over 2-4 days to avoid rebound hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release tablet: Kapvay: Swallow whole; do not crush, split, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal patch: Patches should be applied weekly at a consistent time to a clean, hairless area of the upper outer arm or chest. Rotate patch sites weekly. Redness under patch may be reduced if a topical corticosteroid spray is applied to the area before placement of the patch (Tom 1994). Dispose of any used or unused patches by folding adhesive ends together, replace in pouch or sealed container, and discard properly in trash away from children and pets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153459\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Management of  hypertension (monotherapy or as adjunctive therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Kapvay): Treatment of attention-deficit/hyperactivity disorder (ADHD) (monotherapy or as adjunctive therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Epidural (Duraclon): For continuous epidural administration as adjunctive therapy with opioids for treatment of severe cancer pain in patients tolerant to or unresponsive to opioids alone; epidural clonidine is generally more effective for neuropathic pain and less effective (or possibly ineffective) for somatic or visceral pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal patch: Management of hypertension (monotherapy or as adjunctive therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Note:</b> According to the Eighth Joint National Committee (JNC 8) guidelines, clonidine is <b>not</b> recommended for the initial treatment of hypertension (James 2013). According to the AHA/ACC/ASH 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD), clonidine should be avoided for the treatment of hypertension in patients with heart failure (with reduced ejection fraction) of ischemic origin (AHA/ACC/ASH [Rosendorff 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722040\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Clozapine-induced sialorrhea; Conduct disorder/oppositional defiant disorder with or without attention-deficit/hyperactivity disorder (ADHD) (children and adolescents); Diagnosis of pheochromocytoma; Growth hormone stimulation test; Hot flashes; Opioid withdrawal; Tourette syndrome (adults); Tourette syndrome (children/adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153543\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CloNIDine may be confused with Clomid, clomiPHENE, clonazePAM, cloZAPine, KlonoPIN, quiNIDine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Catapres may be confused with Cataflam, Combipres</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Clonidine is identified in the  Beers Criteria as a potentially inappropriate medication in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers. Avoid clonidine as a first-line antihypertensive (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use caution when interpreting dosing information. Pediatric dose for epidural infusion expressed as mcg/kg/<b>hour</b>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. Errors have occurred when the inactive, optional adhesive cover has been applied instead of the active clonidine-containing patch.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153448\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral, Transdermal:</b> Incidence of adverse events may be less with transdermal compared to oral due to the lower peak/trough ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Drowsiness (2% to 38%), headache (1% to 29%), fatigue (4% to 16%), dizziness (2% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Dermatologic: Transient skin rash (localized; characterized by pruritus and erythema; transdermal 15% to 50%), contact dermatitis (transdermal 8% to 34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Gastrointestinal: Xerostomia (&le;40%), upper abdominal pain (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular: Bradycardia (&le;4%), edema (3%), localized blanching (transdermal 1%), palpitations (1%), tachycardia (&le;3%), atrioventricular block, cardiac arrhythmia, cardiac failure, cerebrovascular accident, chest pain, ECG abnormality, flushing, orthostatic hypotension, prolonged Q-T Interval on ECG, Raynaud's phenomenon, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Sedation (3% to 10%), irritability (5% to 9%), nightmares (4% to 9%), insomnia (&le;6%), emotional disturbance (4%), lethargy (3%), nervousness (1% to 3%), depression (1%), throbbing (transdermal 1%), withdrawal syndrome (1%), aggressive behavior, agitation, anxiety, behavioral changes, delirium, delusions, hallucination (visual and auditory), malaise, numbness (localized; transdermal), paresthesia, parotid pain (oral), restlessness, vivid dream</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Localized vesiculation (transdermal 7%), allergic contact sensitivity (transdermal 5%), hyperpigmentation (transdermal 5%), burning sensation of skin (transdermal 3%), excoriation (transdermal 3%), macular eruption (1%), papule (transdermal 1%), alopecia, hypopigmentation (localized; transdermal), pallor, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia (1%), weight gain (&lt;1%), decreased libido, hyperglycemia (transient; oral), increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (1% to 10%), viral gastrointestinal infection (5%), anorexia (1%), abdominal pain (oral), diarrhea, gastrointestinal pseudo-obstruction (oral), nausea, parotitis (oral), sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary incontinence (4%), sexual disorder (3%), erectile dysfunction (2% to 3%), nocturia (1%), pollakiuria, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocytopenia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests (mild transient abnormalities; &lt;1%), hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (10%), tremor (1% to 4%), arthralgia (1%), myalgia (1%), leg cramps (&lt;1%), increased creatine phosphokinase (transient; oral), limb pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Accommodation disturbance, blurred vision, burning sensation of eyes, decreased lacrimation, dry eye syndrome, increased lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Otitis media (&le;3%), otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Asthma, dry nose, epistaxis, flu-like symptoms, nasal congestion, nasopharyngitis, respiratory tract infection, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Crying (1% to 3%), fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Epidural:</b> <b>Note:</b> The following adverse events occurred more often than placebo in cancer patients with intractable pain being treated with concurrent epidural morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (45%), orthostatic hypotension (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Confusion (13%), dizziness (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Xerostomia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Hallucination (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea and vomiting (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus (5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153463\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clonidine hydrochloride or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Epidural administration: Injection site infection; concurrent anticoagulant therapy; bleeding diathesis; administration above the C4 dermatome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153445\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: May cause dose-dependent reductions in heart rate; use with caution in patients with preexisting bradycardia or those predisposed to developing bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Symptomatic hypotension may occur with use. In all patients, use epidural clonidine with caution due to the potential for severe hypotension, especially in women and those of low body weight. Most hypotensive episodes occur within the first 4 days of initiation; however, episodes may occur throughout the duration of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Epidural administration may result in mild respiratory depression (usually associated with higher than recommended doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Xerostomia: May cause significant xerostomia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, including recent MI and conduction disturbances, including sinus node dysfunction. The use of epidural clonidine frequently reduces heart rate; AV block greater than first-degree has been reported rarely. Epidural clonidine is not recommended for use in patients with severe cardiovascular disease or hemodynamic instability. May lead to cardiovascular instability (hypotension, bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with chronic renal impairment. The hemodynamic effects may be prolonged in those with renal impairment; elimination half-life significantly prolonged (up to 41 hours) in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Agents with SA/AV nodal blocking properties: Use with caution in patients concurrently receiving agents known to reduce SA node function and/or AV nodal conduction (eg, digoxin, diltiazem, metoprolol, verapamil); may increase risk of serious bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depressants: Sedating effects may be potentiated when used with other CNS-depressant drugs or ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Since children commonly have gastrointestinal illnesses with vomiting, they are susceptible to hypertensive episodes due to abrupt inability to take oral medication. Epidural clonidine should be reserved for pediatric cancer patients with severe intractable pain, unresponsive to other analgesics or epidural or spinal opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Discontinue oral immediate-release formulations within 4 hours of surgery, then restart as soon as possible afterward.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural use: <b>[US Boxed Warning]: Must dilute concentrated epidural injectable (500 mcg/mL) solution prior to use. Epidural clonidine is not recommended for perioperative, obstetrical, or postpartum pain due to risk of hemodynamic instability.</b> Should be administered via continuous epidural infusion device. Monitor closely for catheter-related infection such as meningitis or epidural abscess.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Oral formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Localized contact sensitization to the transdermal system has been reported; in these patients, allergic reactions (eg, generalized rash, urticaria, angioedema) have also occurred following subsequent substitution of oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Clonidine may cause eye dryness in patients who wear contact lenses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Gradual withdrawal is needed (taper oral immediate release or epidural dose gradually over 2 to 4 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuation (causes rapid increase in BP and symptoms of sympathetic overactivity). In patients on both a beta-blocker and clonidine where withdrawal of clonidine is necessary, withdraw the beta-blocker first and several days before clonidine withdrawal, then slowly decrease clonidine. In children and adolescents, extended release formulation (Kapvay) should be tapered in decrements of no more than 0.1 mg every 3 to 7 days. The clonidine withdrawal syndrome is more pronounced after abrupt cessation of long-term therapy than after short-term therapy (1 to 2 months). It has usually been associated with previous administration of high oral doses (&gt;1.2 mg daily in adults) and/or continuation of beta-blocker therapy. The danger of abrupt discontinuation may be increased in patients with hypertension and/or other cardiovascular considerations. Blood pressure may increase 8 to 24 hours after last dose, but has occurred 60 hours after the last clonidine dose. Rebound hypertension has occurred with discontinuation of transdermal and epidural clonidine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299067\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153450\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9285&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): CloNIDine may enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: CloNIDine may enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): CloNIDine may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: CloNIDine may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of CloNIDine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153451\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153467\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Clonidine crosses the placenta; concentrations in the umbilical cord plasma are similar to those in the maternal serum and concentrations in the amniotic fluid may be 4 times those in the maternal serum. The pharmacokinetics of clonidine may be altered during pregnancy (Buchanan 2009). Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2012). <b>[US Boxed Warning]: Epidural clonidine is not recommended for obstetrical or postpartum pain</b> due to risk of hemodynamic instability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153468\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Clonidine is excreted in breast milk. Concentrations have been noted as ~7% to 8% of those in the maternal plasma following oral dosing (Atkinson 1988; Bunjes 1993) and twice those in the maternal serum following epidural administration. The manufacturer recommends caution be used if administered to nursing women. Another source recommends avoiding use when nursing infants born &lt;34 weeks gestation or when large maternal doses are needed (Atkinson 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153453\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, standing and sitting/supine, mental status, heart rate</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure (when started and weaned), and consider obtaining ECG prior to initiation (Vetter 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Clonidine tolerance test: In addition to growth hormone concentrations, monitor blood pressure and blood glucose (Huang 2001).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Epidural: Carefully monitor infusion pump; inspect catheter tubing for obstruction or dislodgement to reduce risk of inadvertent abrupt withdrawal of infusion. Monitor closely for catheter-related infection (eg, meningitis or epidural abscess).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153444\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha<sub>2</sub>-adrenoceptors in the brain stem, thus activating an inhibitory neuron, resulting in reduced sympathetic outflow from the CNS, producing a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure; epidural clonidine may produce pain relief at spinal presynaptic and postjunctional alpha<sub>2</sub>-adrenoceptors by preventing pain signal transmission; pain relief occurs only for the body regions innervated by the spinal segments where analgesic concentrations of clonidine exist. For the treatment of ADHD, the mechanism of action is unknown; it has been proposed that postsynaptic alpha<sub>2</sub>-agonist stimulation regulates subcortical activity in the prefrontal cortex, the area of the brain responsible for emotions, attentions, and behaviors and causes reduced hyperactivity, impulsiveness, and distractibility. Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce analgesia at presynaptic and postjunctional alpha-2-adrenoceptors in the spinal cord by preventing pain signal transmission to the brain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153462\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antihypertensive effect: Transdermal: Steady state reached in ~3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Attention-deficit/hyperactivity disorder: Oral: Extended release (Kapvay): Onset of action: 1 to 2 weeks (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Extended-release tablets (Kapvay) are not bioequivalent with immediate-release formulations; peak plasma concentrations are 50% lower compared to immediate-release formulations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~2.9 L/kg; highly lipid soluble; distributes readily into extravascular sites</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Epidurally administered clonidine readily distributes into plasma via the epidural veins and attains clinically significant systemic concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 20% to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic to inactive metabolites; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Immediate release: 70% to 80%; Extended release (Kapvay): ~89% (relative to immediate-release formulation); Transdermal: ~60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 6.13 &plusmn; 1.33 hours (Lonnqvist 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: 12 to 16 hours; Renal impairment: &le;41 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Epidural administration: CSF half-life elimination: 1.3 &plusmn; 0.5 hours; plasma half-life elimination: 22 &plusmn; 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal: Half-life elimination (after patch removal): ~20 hours (due to skin depot effect; increase in plasma clonidine concentrations may occur after patch removal [MacGregor 1985])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral: Immediate release: 1 to 3 hours; Extended release (Kapvay): 7 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (40% to 60% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance:</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Neonates: 0.16 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Infants and Children &le;4 years: ~0.3 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Children 5 to 10 years: ~0.26 L/kg/hour (Xie 2011)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Adults: Single dose: ~0.25 L/kg/hour; Multiple dose: ~0.4 L/kg/hour (Frisk-Holmberg 1981)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153466\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-1 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (4): $292.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-2 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/24 hrs (4): $492.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (Catapres-TTS-3 Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/24 hrs (4): $683.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch weekly</b> (CloNIDine HCl Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/24 hrs (1): $33.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/24 hrs (1): $55.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/24 hrs (1): $77.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CloNIDine HCl (Analgesia) Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (10 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (10 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Duraclon Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (10 mL): $52.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (10 mL): $264.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (CloNIDine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (60): $269.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Kapvay Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (60): $530.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Catapres Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $301.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $461.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $579.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (CloNIDine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $37.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg (100): $52.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038585\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alphapres (PH);</li>\n      <li>Arkamin (IN);</li>\n      <li>Aruclonin (HU);</li>\n      <li>Atensina (BR);</li>\n      <li>Catamed (PH);</li>\n      <li>Catapin (PH);</li>\n      <li>Catapres (AU, BB, BD, BF, BH, BJ, BM, BS, BZ, CI, CY, ET, GB, GH, GM, GN, GY, HK, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NZ, OM, PH, PK, PR, QA, SA, SC, SD, SG, SL, SN, SR, TN, TT, TW, TZ, UG, ZM, ZW);</li>\n      <li>Catapresan (AR, AT, CH, CL, CO, CR, DE, DK, DO, EC, ES, FI, GR, GT, HN, HR, IS, IT, NI, NL, NO, PA, PE, PT, SE, SI, SV, VE);</li>\n      <li>Catapresan Depot (CZ, DE);</li>\n      <li>Catapresan TTS (IT);</li>\n      <li>Catapress (AE, EG);</li>\n      <li>Catapressan (BE, FR, LU, VN);</li>\n      <li>Chlophazolin (BG, LV);</li>\n      <li>Clonidina Larjan (AR);</li>\n      <li>Clonidural (AR);</li>\n      <li>Clonigen (PH);</li>\n      <li>Clonipresan (PY);</li>\n      <li>Clonipress (PH);</li>\n      <li>Dixarit (IE, LU, NZ);</li>\n      <li>Haemiton (DE, IL);</li>\n      <li>Hylon (BD);</li>\n      <li>Hypodine (TH);</li>\n      <li>Iporel (PL);</li>\n      <li>Isoglaucon (HU);</li>\n      <li>Jenloga (BM);</li>\n      <li>Kapvay (BM);</li>\n      <li>Kapvay ER (KR);</li>\n      <li>Melzin (PH);</li>\n      <li>Menograine (ZA);</li>\n      <li>Normopresan (IL);</li>\n      <li>Normopresin (UY);</li>\n      <li>Paracefan (BE);</li>\n      <li>Run Rui (CN);</li>\n      <li>Terclodine (PH);</li>\n      <li>Winpress (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&quot; <i>Pediatrics</i>, 2011; 128(5): 1-16.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 1):396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/22270315/pubmed\" target=\"_blank\" id=\"22270315\">22270315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkin SH, Jaker MA, Beaty P, et al, &ldquo;Oral Labetalol Versus Oral Clonidine in the Emergency Treatment of Severe Hypertension,&rdquo; <i>Am J Med Sci</i>, 1992, 303(1):9-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/1728876/pubmed\" target=\"_blank\" id=\"1728876\">1728876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkinson HC, Begg EJ, and Darlow BA, &quot;Drugs in Human Milk. Clinical Pharmacokinetic Considerations,&quot; <i>Clin Pharmacokinet</i>, 1988, 14(4):217-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3292101 /pubmed\" target=\"_blank\" id=\"3292101 \">3292101 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buchanan ML, Easterling TR, Carr DB, et al, &quot;Clonidine Pharmacokinetics in Pregnancy,&quot; <i>Drug Metab Dispos</i>, 2009, 37(4):702-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19116263/pubmed\" target=\"_blank\" id=\"19116263\">19116263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bunjes R, Schaefer C, and Holzinger D, &quot;Clonidine and Breast-Feeding,&quot; <i>Clin Pharm</i>, 1993, 12(3):178-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8491075/pubmed\" target=\"_blank\" id=\"8491075\">8491075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cahill K, Stevens S, Perera R, Lancaste T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. <i>Cochrane Database Syst Rev.</i> 2013;(5):CD009329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23728690/pubmed\" target=\"_blank\" id=\"23728690\">23728690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catapres (clonidine hydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capogna G, Celleno D, Zangrillo A, et al, &ldquo;Addition of Clonidine to Epidural Morphine Enhances Postoperative Analgesia After Cesarean Delivery,&rdquo; <i>Reg Anesth</i>, 1995, 20(1):57-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7727330/pubmed\" target=\"_blank\" id=\"7727330\">7727330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10660814\"></a>Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. <i>Clin Pediatr (Phila)</i>. 2000;39(1):15-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/10660814/pubmed\" target=\"_blank\" id=\"10660814\">10660814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corazza M, Mantovani L, Virgil A, et al, &ldquo;Allergic Contact Dermatitis From a Clonidine Transdermal Delivery System,&rdquo; <i>Contact Dermatitis</i>, 1995, 32(4):246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7600788/pubmed\" target=\"_blank\" id=\"7600788\">7600788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham FE, Baughman VL, Peters J, et al, &ldquo;Comparative Pharmacokinetics of Oral versus Sublingual Clonidine,&rdquo; <i>J Clin Anesth</i>, 1994, 6(5):430-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7986518/pubmed\" target=\"_blank\" id=\"7986518\">7986518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duraclon (clonidine hydrochloride injection) [prescribing information]. Lake Forest, IL: Bioniche Pharma; August 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitzgibbon D, Rapp S, Butler S, et al, &ldquo;Rebound Hypertension and Withdrawal Associated With Discontinuation of an Infusion of Epidural Clonidine,&rdquo; <i>Anesthesiology</i>, 1996, 84(3):729-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8659804/pubmed\" target=\"_blank\" id=\"8659804\">8659804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiore MC, Jaen CR, Baker TB, et al, <i>Treating Tobacco Use and Dependence: 2008 Update.</i> Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. Available at <a href=\"http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf\" target=\"_blank\">http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7332729\"></a>Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man&mdash;evidence for dose dependency and changed pharmacokinetics during chronic therapy. <i>Br J Clin Pharmacol</i>. 1981;12(5):653-658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7332729/pubmed\" target=\"_blank\" id=\"7332729\">7332729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11886028\"></a>Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(3):330-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11886028/pubmed\" target=\"_blank\" id=\"11886028\">11886028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27140827\"></a>Gowing L, Farrell M, Ali R, White JM. Alpha&#8322;-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database Syst Rev</i>. 2016:3;(5):CD002024. doi: 10.1002/14651858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/27140827/pubmed\" target=\"_blank\" id=\"27140827\">27140827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1552044\"></a>Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. <i>J Clin Psychopharmacol</i>. 1992;12(1):69-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/1552044/pubmed\" target=\"_blank\" id=\"1552044\">1552044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hart-Santora D and Hart LL, &ldquo;Clonidine in Attention Deficit Hyperactivity Disorder,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(1):37-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/1606344/pubmed\" target=\"_blank\" id=\"1606344\">1606344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19433274\"></a>Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. <i>Pediatr Neurol</i>. 2009;40(6):420-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19433274/pubmed\" target=\"_blank\" id=\"19433274\">19433274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang C, Banergee K, Sochett E, et al, &ldquo;Hypoglycemia Associated With Clonidine Testing for Growth Hormone Deficiency,&rdquo; <i>J Pediatr</i>, 2001, 139(2):323-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11487765/pubmed\" target=\"_blank\" id=\"11487765\">11487765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaker M, Atkin S, Soto M, et al, &ldquo;Oral Nifedipine vs Oral Clonidine in the Treatment of Urgent Hypertension,&rdquo; <i>Arch Intern Med</i>, 1989, 149(2):260-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/2916871/pubmed\" target=\"_blank\" id=\"2916871\">2916871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients,&rdquo; <i>Am J Kidney Dis</i>, 2005, 45(4 Suppl 3):46-57.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi:10.1097/ADM.0000000000000166. http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=1826406300</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kapvay (clonidine) [prescribing information]. St. Michael, Barbados: Concordia; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8496122\"></a>Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(3):577-581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8496122/pubmed\" target=\"_blank\" id=\"8496122\">8496122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleber HD, Weiss RD, Anton RF Jr, et al. American Psychiatric Association. Treatment of opioid-related disorders. Practice guideline for the treatment of patients with substance use disorders. 2nd edition. http://www.psychiatryonline.com/content.aspx?aID=142306. Published August 2006. Accessed March 31, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanes R and Hurtado E, &ldquo;Oral Clonidine - an Effective Growth Hormone-releasing Agent in Prepubertal Subjects,&rdquo; <i>J Pediatric</i>, 1982, 100(5):710-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7040621/pubmed\" target=\"_blank\" id=\"7040621\">7040621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lonnqvist PA, Bergendahl H. Pharmacokinetics and haemodynamic response after an intravenous bolus injection of clonidine in children. <i>Paediatric Anaesthesia</i>. 1993;3:359-364.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor TR, Matzek KM, Keirns JJ, et al, &ldquo;Pharmacokinetics of Transdermally Delivered Clonidine,&rdquo; <i>Clin Pharmacol Ther</i>, 1985, 38(3):278-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/4028622/pubmed\" target=\"_blank\" id=\"4028622\">4028622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matuschka PR, &ldquo;Safer Alternatives to Sublingual Nifedipine for the Treatment of Hypertensive Urgencies,&rdquo; <i>J Pharm Technol</i>, 1999, 15:199-203.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. <i>Clin Pharmacol Ther</i>. 1988;43(4):363-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3281774/pubmed\" target=\"_blank\" id=\"3281774\">3281774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2693002\"></a>Morselli PL, Boutroy MJ, Bianchetti G, et al. Pharmacokinetics of antihypertensive drugs in the neonatal period.<i> Dev Pharmacol Ther</i>. 1989;13(2-4):190-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/2693002/pubmed\" target=\"_blank\" id=\"2693002\">2693002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naja ZM, Maaliki H, Al-Tannir MA, El-Rajab M, Ziade F, Zeidan A. Repetitive paravertebral nerve block using a catheter technique for pain relief in post-herpetic neuralgia. <i>Br J Anaesth</i>. 2006;96(3):381-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/16431881/pubmed\" target=\"_blank\" id=\"16431881\">16431881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at https://www.nice.org.uk/guidance/CG72</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NHBPEP (National High Blood Pressure Education Program) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.&rdquo; Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18182963\"></a>Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(2):180-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18182963/pubmed\" target=\"_blank\" id=\"18182963\">18182963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15983000\"></a>Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea? <i>J Psychopharmacol</i>. 2005;19(4):426-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15983000/pubmed\" target=\"_blank\" id=\"15983000\">15983000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/22397999/pubmed\" target=\"_blank\" id=\"22397999\">22397999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richmond EJ and Rogol AD, &ldquo;Growth Hormone Deficiency in Children,&rdquo; <i>Pituitary</i>, 2008, 11(2):115-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18425584/pubmed\" target=\"_blank\" id=\"18425584\">18425584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocchini AP, &ldquo;Childhood Hypertension: Etiology, Diagnosis, and Treatment,&rdquo; <i>Pediatr Clin North Am</i>, 1984, 31(6):1259-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/6390314/pubmed\" target=\"_blank\" id=\"6390314\">6390314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25840695/pubmed\" target=\"_blank\" id=\"25840695\">25840695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/21445724/pubmed\" target=\"_blank\" id=\"21445724\">21445724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scahill L, &quot;Alpha-2 Adrenergic Agonists in Attention Deficit Hyperactivity Disorder,&quot; <i>J Pediatr</i>, 2009, 154(5 Suppl):32-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt GR and Schuna AA, &ldquo;Rebound Hypertension After Discontinuation of Transdermal Clonidine,&rdquo; <i>Clin Pharm</i>, 1988, 7(10):772-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3233898/pubmed\" target=\"_blank\" id=\"3233898\">3233898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinaiko AR, &ldquo;Pharmacologic Management of Childhood Hypertension,&rdquo; <i>Pediatr Clin North Am</i>, 1993, 40(1):195-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8417406/pubmed\" target=\"_blank\" id=\"8417406\">8417406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tom GR and Premer M, &quot;Hydrocortisone Cream in Clonidine Patch Dermatitis,&quot; <i>Ann Pharmacother</i>, 1994, 28(7-8):889-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7949510/pubmed\" target=\"_blank\" id=\"7949510\">7949510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. <i>Neurology.</i> 2002;58(4):527-536.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11865128/pubmed\" target=\"_blank\" id=\"11865128\">11865128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Veteran Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the management of substance use disorders. Version 3.0. Updated 2015. Available at: <a href=\"https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf\" target=\"_blank\">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23099282\"></a>Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23099282/pubmed\" target=\"_blank\" id=\"23099282\">23099282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20484620\"></a>Xie HG, Cao YJ, Gauda EB, Agthe AG, Hendrix CW, Lee H. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. <i>J Clin Pharmacol</i>. 2011;51(4):502-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/20484620/pubmed\" target=\"_blank\" id=\"20484620\">20484620</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9285 Version 279.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708678\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F153485\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F153486\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F153534\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F153489\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F153510\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F153490\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F153491\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795877\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F153455\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F153441\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23610340\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F153460\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F153459\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722040\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F153543\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153448\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153463\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153445\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299067\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F153450\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F153451\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F153467\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F153468\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F153453\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153444\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F153462\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F153466\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038585\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9285|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clonidine-patient-drug-information\" class=\"drug drug_patient\">Clonidine: Patient drug information</a></li><li><a href=\"topic.htm?path=clonidine-pediatric-drug-information\" class=\"drug drug_pediatric\">Clonidine: Pediatric drug information</a></li></ul></div></div>","javascript":null}